本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total 25 billion yen in new Series B funding and raised 22.5 billion yen with the first payment. This significant investment brings the company's total funding to 44 billion yen. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy. Investor Statements DCI Partners Co., Ltd."We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro." JIC Venture Growth Investments Co., Ltd."We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases." Kyoto University Innovation Capital Co., Ltd."We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible." JAFCO Group Co., Ltd."We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options." Mitsubishi UFJ Capital Co., Ltd."Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice." Series B investors DCI Partners Co., Ltd. JIC Venture Growth Investments Co., Nippon Venture Capital CO., Ltd TOHOKU University Venture Partners Co., Ltd. Golden Asia Fund Ventures Ltd. Mitsui Chemicals, Inc. Global Brain Corporation Kyoto University Innovation Capital Co., Ltd. JAFCO Group Co., Ltd. Mitsubishi UFJ Capital Co., Ltd. QB Capital, LLC Industrial Technology Investment SHIMADZU CORPORATION SCREEN Holdings Co., Ltd. Chushin Venture Capital Co.,Ltd. SENSHU IKEDA CAPITAL CO.,LTD. Toyo Seikan Group Holdings, Ltd. ASAHI KASEI CORPORATION i-Lab CVC1 Limited Liability Partnership Others About Rege Nephro Co., Ltd. Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases. About RN-014 Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time. About RN-032 Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments.
HONG KONG, Oct. 7, 2024 /PRNewswire/ -- GreenCo, a specialised sustainability consultancy with a presence in Hong Kong and Singapore, is recently making waves in the business world by taking a more holistic approach to sustainability consulting. While many firms focus solely on helping clients prepare sustainability disclosure reports, GreenCo recognises the need to influence the entire investment and business ecosystem. Sustainability Consulting Beyond Disclosure Recently, GreenCo has forged partnerships with asset managers, venture capital funds, and other key players in the investment chain. It recognises that to drive meaningful, large-scale change, it must engage with the first step of the investment process. "Our sustainability consulting services go far beyond just helping organisations craft sustainability reports," explained Max Tsang, the Director of GreenCo. "We take a broader, more strategic view of how sustainability is shaping the investment landscape and driving change across industries." "We have seen the advanced context in which sustainability consulting is influencing and reshaping the investment chain and business world", said Max. "That's why we have made a concerted effort to work closely with asset managers and funds, especially venture capital funds, to help them integrate sustainability into their investment decision-making." Formalising Responsible Investment Policies Through these partnerships, GreenCo is helping investment firms formalise their Responsible Investment Policies and develop ESG integration tools. By embedding sustainability-focused values and considerations into the investment process, GreenCo aims to create a ripple effect that drives change across the business landscape. "Many investment firms recognise the importance of sustainability, but struggle to translate that into concrete policies and practices," explained Max. "We work hand-in-hand with them to create tailored frameworks that align with their investment thesis and stakeholder expectations." Driving Change in the Whole Investment Chain GreenCo's holistic approach extends beyond just the investment community. It also works closely with its corporate clients to help them navigate the evolving sustainability landscape and align their business strategies with the demands of the investment chain. Dr. Charlie Yang, the Director and Head of GreenCo Singapore, shared his thought that it was not enough to simply help organisations prepare their sustainability reports. "We need to empower the entire investment chain to prioritise and integrate sustainability, from the venture capitalists all the way down to the companies they invest in," he added. This multi-faceted approach is already yielding tangible results. GreenCo's partnerships with asset managers and venture capital funds have led to the development of robust Responsible Investment Policies and ESG integration frameworks that are driving change across their investment portfolios. "The impact of our work is not confined to individual organisations," explained Dr. Yang. "By working with the first step of the investment chain, we are able to catalyse large-scale change that triggers "chain-reaction" in the business world." A Diverse Expert Team GreenCo's aspiration is underpinned by the diversity of its expert team. The consultancy boasts a mix of professionals with backgrounds in business, finance, accounting, and environmental science. "We understand the language of the business world because many of our team members have hands-on experience in corporate finance and strategy. At the same time, we have deep expertise in environmental and sustainability issues, which allows us to bridge the gap between the boardroom and the natural world," added Max. "I believe this unique blend of skills and perspectives sets GreenCo apart from its peers, enabling us to provide a more holistic and impactful sustainability consulting service." Looking to the Future As the importance of sustainability continues to grow, GreenCo is committed to expanding its holistic consulting services and deepening its partnerships across the investment ecosystem. GreenCo believes that sustainability is no longer a siloed concern, but a critical driver of business success and financial performance. By taking a comprehensive, collaborative approach, GreenCo can help its partners navigate this rapidly evolving landscape and create a more sustainable future. About GreenCo GreenCo ESG Advisory Limited has been focusing on ESG reporting and sustainability advisory since 2016. Having been a member of sustainability associations such as GRI Community and Business Environment Council for years, GreenCo's professional consulting group is committed to designing and providing tailored ESG advisory services. GreenCo has collaborated with over 60 listed companies and fund managers in Hong Kong and Singapore, as well as businesses worldwide, representing diverse industries in the Hang Seng Industry Classification System. GreenCo follows international and local frameworks, including Appendix C2 (previously known as Appendix 27 / 20) – ESG Reporting Guide published by the Stock Exchange of Hong Kong Limited, United Nations Sustainable Development Goals (UN SDGs), United Nations Principles for Responsible Investment (UN PRI), Global Reporting Initiative (GRI), Task Force on Climate-related Financial Disclosures (TCFD), IFRS S2 Climate-related Disclosures, CDP Guidance Documentation and Questionnaires and S&P Corporate Sustainability Assessment. By utilising these frameworks, GreenCo offers comprehensive advisory support, delivering cutting-edge, insightful and practical solutions to our clients and various industry sectors on their journey towards transparency, sustainability, and resilience. For more details, please visit our website: www.greenco-esg.com or www.greenco-esg.sg or access our ESG public portal: https://greenco.app Media Contact：Email: esg@greenco-esg.comWhatsApp: +65 88891148
SINGAPORE - Media OutReach Newswire - 2 October 2024 - Leading digital asset trading group Caladan is proud to announce the opening of its over-the-counter crypto options desk to offer crypto structured products for institutional and accredited investors. Caladan Announces Options and Structured Products Desk Strategic Expansion Into Structured Products Caladan’s decision to expand into structured products is a natural expansion of how it partners with crypto token projects, and as a leading crypto trading firm, it is highly synergistic with its existing venture capital investing and market-making activities. “For years, we’ve supported crypto startups at their very earliest stages as a venture capital investor, and also at token listing with our crypto market-making capabilities across CEFI and DEFI”, said John Gu, CEO of the Caladan Group, “Now, we are expanding further across the token project lifecycle by providing treasury solutions for token foundations and key investors that will enable them to protect and leverage their investments.” Remi Colinmaire Appointed as Head of Options Trading Caladan has appointed Remi Colinmaire as its Head of Options Trading. Colinmaire, who is based out of the Caladan Group’s Singapore office, brings over twenty years of experience in options and volatility trading to the role. He began his career as an options market-maker at BNP Paribas, and has previously been a Managing Director at Goldman Sachs and a Portfolio Manager at AlphaDyne Asset Management specialising in index volatility trading. “I am delighted to join Caladan to build out the crypto structured products and options business”, said Colinmaire. "Despite being a nascent market, digital assets options are poised to grow tremendously from here as more institutions and sophisticated investors are looking for capital efficient financing solutions.," he added. Options Products Available on Long Tail Tokens As an alt-coin specialist, Caladan will be offering a range of derivative solutions on a large number of different tokens, including crypto hedging solutions, treasury solutions, and various crypto yield products as well. These crypto structured products will allow token foundations and institutional investors to generate yield on and hedge the risk of their holdings, including through crypto OTC options for large transactions. “Token foundations and institutional investors often don’t want to sell their holdings as they believe in the project for the long run”, said Will Leung, Caladan’s Head of Business Development. “Instead, we are seeing increased demand from the most savvy foundations and investors for solutions to be able to monetize their holdings, combining a crypto market making strategy with hedging to protect capital. More information on hedging and protection strategies may be found on the Caladan website. Caladan Group’s structured products solutions will only be available to institutions and accredited investors subject to strict customer due diligence. These products are not offered to retail investors or the general public in Singapore. Hashtag: #CaladanGroup #CryptoOptions #CryptoStructuredProducts #OTCTrading #Caladanhttps://caladan.xyz/https://www.linkedin.com/company/caladanxyzhttps://x.com/caladanxyzhttps://www.youtube.com/@caladanxyzThe issuer is solely responsible for the content of this announcement.About CaladanCaladan makes digital asset markets more efficient and fair. We support exchanges, tokens, and institutional investors with on-exchange liquidity, DeFi expertise, treasury solutions, and investments. Since 2017 we've been a pioneer in crypto market-making, powering over $50B in annual transactions across 1000+ assets.
TAIPEI, Oct. 2, 2024 /PRNewswire/ -- Aiello, a leading startup specializing in Natural Language Processing (NLP), announced today the successful completion of a US$5 million funding round. The round was led by prominent Japanese venture capital firms Cool Japan Fund and CDIB Cross Border Innovation Fund II LP, along with E.Sun Venture Capital Co., Ltd., and B Current Mstar Impact Investment. Additional support came from existing institutional backers, JAFCO Asia and Wistron Corporation, further reinforcing confidence in Aiello's strategic direction. As part of this round, Aiello welcomed Kenichi Sawaya from CDIB Cross Border Innovation Fund II LP, a Co-GP fund between CDIB and Cool Japan Fund, to join the board of directors. Sawaya brings a wealth of global experience and strategic insight, which will be instrumental in accelerating Aiello's expansion into Japan. "We are excited to participate in Aiello's latest funding round. Their AI expertise and innovative, all-in-one hospitality management system will address operational inefficiencies and fragmentation in the hospitality sector, driving sustainable growth amid ongoing labor shortages. We look forward to advancing the digital transformation and elevating hotel services in Japan through this partnership," Sawaya said. Aiello CEO and co-founder Vic Shen commented, "This funding round is primarily about bringing on board shareholders who offer invaluable experience for our growth. The capital raised will support our international expansion, particularly in Japan and Southeast Asia. Beyond expanding our reach, we aim to collaborate with local software and service providers to adapt and enhance the Aiello Hospitality Platform, creating a fully localized, all-in-one SaaS solution that can replace outdated systems." In 2023, Aiello launched Aiello-One, an all-in-one SaaS management platform designed specifically for the hospitality industry. The platform offers three core modules: Interface, Operations, and Insight. These modules simplify the adoption of digital solutions, while the platform's flexible plugin system enables continuous upgrades. This approach allows hotels to reduce maintenance costs and easily tailor the system to meet their unique operational needs. Aiello launched its all-in-one SaaS platform, Aiello-One, in 2023, featuring three key modules: Interface, Operations, and Insight. Aiello’s platform has processed over 4.71 million guest requests and cross-departmental tasks, facilitating more than 55.1 million guest interactions through its voice and touch functionalities, while supporting over 2.8 million room nights to date. Aiello's international partnerships have surged, with 65% of its new contracts in 2023 coming from global hotel chains such as Seibu Prince Hotels & Resorts, Millennium Hotels and Resorts, and Taiwan's Cosmos Hotels & Resorts and Caesar Park Hotels & Resorts. Over the past three years, Aiello has been implemented in more than 180 hotels, covering over 20,000 rooms. The platform has processed over 4.71 million guest requests and cross-departmental tasks, while its voice and touch functionalities have facilitated over 55.1 million guest interactions. To date, Aiello has supported more than 2.8 million room nights, providing personalized service and real-time responses to meet the diverse needs of modern travelers. Looking ahead to 2025-2027, Aiello is well-positioned to address critical industry challenges, including labor shortages, the growing number of new hotels, and the rising demand for brand renovations. The shift from traditional on-premise servers to AI-powered in-room devices is expected to elevate the industry to new heights of technological innovation. Starting in Q3 2024, Aiello has partnered with service and content providers to offer diversified travel itineraries and shopping services directly in guest rooms, aiming to further enhance guest experiences and drive hotel revenue growth. About Aiello Aiello is a leading provider of Voice AI in the hospitality industry. Its flagship product, Aiello Voice Assistant, is a multi-award-winning talk & touch voice AI technology solution aimed at streamlining hotel operations, enhancing the guest experience, and generating insights about customer behavior. The state-of-the-art Aiello Voice Assistant is designed to elevate the guest experience with its unique AI-powered features and capabilities. Since 2019, Aiello Voice Assistant has been deployed in over 180 hotels, encompassing 20,000 rooms, and has answered over 14 million inquiries from 2.5 million end users in Chinese, Japanese, Thai, and English. Learn more at Aiello's official website: https://aiello.ai/ For further information, please contact: Patty Chen Marketing Director, Aiello Email: patty.chen@aiello.ai Patricia Wang PR/Event Marketing Manager, Aiello Email: patricia.wang@aiello.ai
NEW YORK, Oct. 2, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances), and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited ("PubCo"), and its shares and warrants will commence trading on the Nasdaq under the ticker symbols "BDMD" and "BDMDW", respectively, on October 2, 2024. On September 26, 2024, ExcelFin held a special meeting of its stockholders (the "Special Meeting") to consider and vote upon a proposal to approve the Business Combination described in the proxy statement/prospectus. At the Special Meeting, in person or by proxy, the holders of 6,015,236 shares of ExcelFin's Class A common stock, constituting 91.36% of the issued and outstanding voting capital stock of ExcelFin entitled to vote, were present at the Special Meeting. Approximately 99.9% of the votes cast at the Special Meeting were in favor of approving the Business Combination. Complete official results of the vote are included in a current report on Form 8-K filed by ExcelFin with the U.S. Securities and Exchange Commission (the "SEC"). Upon completion of the Business Combination, founders of Baird Medical and Grand Fortune Capital, LLC, co-sponsor of ExcelFin Acquisition Corporation, subscribed to a $4,900,000 Convertible Preferred investment in the Company. Advisors Dechert LLP is serving as legal counsel to Baird Medical. Allen Overy Shearman Sterling US LLP is serving as legal counsel to ExcelFin. Cohen & Company Capital Markets, a division of J.V.B. Financial Group LLC, is serving as the lead financial advisor and capital markets advisor to ExcelFin, along with EXOS Capital LLC, Roth Capital LLC, and Haitong International Securities (USA) Inc. Additional Information and Where to Find It On June 26, 2023, ExcelFin, Baird Medical, PubCo, Betters Medical Merger Sub, Inc., Betters Medical Merger Sub 2, Inc., Betters Medical NewCo, LLC and Tycoon Choice Global Limited entered into a Business Combination Agreement as amended from time to time (the "Business Combination Agreement"). In connection with the transactions contemplated by the Business Combination Agreement (the "Transactions"), PubCo filed with the SEC a registration statement on Form F-4 (the "Registration Statement") (Registration No. 333-274114). The Registration Statement includes both the proxy statement that was distributed to ExcelFin's stockholders in connection with ExcelFin's solicitation of proxies for the vote by ExcelFin's stockholders with respect to the Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of PubCo to be issued in connection with the Business Combination. The Registration Statement was declared effective by the SEC on September 5, 2024. Stockholders and investors may obtain free copies of the proxy statement/prospectus and other relevant materials and documents filed by PubCo and ExcelFin with the SEC at the SEC's website at www.sec.gov. About Baird Medical Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading microwave ablation ("MWA") medical device manufacturer and provider in China (and a recent entrant to the United States market). Baird Medical's proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung cancer and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit http://www.bairdmed.com/. About ExcelFin ExcelFin is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ExcelFin's sponsors include Grand Fortune Capital, LLC ("GFC") and Fin Venture Capital ("Fin"). GFC is an affiliate of an investment group that completed a series of significant M&A transactions and investments in FinTech, Technology, Media, and Telecommunications and Healthcare. Fin is a private equity firm focused on FinTech software. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or ExcelFin's, Baird Medical's, PubCo's or Tycoon's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by ExcelFin and Baird Medical and their management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. None of PubCo, ExcelFin, or Baird Medical undertakes any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Transactions; (2) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (3) the inability to recognize the anticipated benefits of the Transactions; (4) unexpected costs resulting from the Transactions; (5) changes in general economic conditions; (6) regulatory conditions and developments; (7) changes in applicable laws or regulations; (8) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Transactions and instituted against PubCo, ExcelFin, Baird Medical or others; and (9) other risks and uncertainties from time to time described in the Registration Statement relating to the Transactions, including those listed under the section titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by PubCo in connection with the Transactions. All subsequent written and oral forward-looking statements concerning ExcelFin, Baird Medical, PubCo or Tycoon, the Transactions described herein or other matters attributable to ExcelFin, Baird Medical, PubCo, Tycoon or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of ExcelFin, Baird Medical, PubCo and Tycoon expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. ContactsInvestor RelationsRobin Yang, PartnerICR, LLCPhone: +1 (646) 308-1475Email: BairdMedical.IR@icrinc.com Public RelationsBrad Burgess, Senior Vice PresidentICR, LLCPhone: +1 (646) 588-0383Email: BairdMedical.PR@icrinc.com
At the end of September 2024, Hong Kong stocks experienced a dramatic rebound, with the Hang Seng Index surging back above 20,000 points and achieving a record single-day trading volume exceeding HKD 445.7 billion, marking one of the most active trading days in the history of Hong Kong equities. Concurrently, in the latest global financial center rankings, Hong Kong has returned to the top three, reinstating the "Nylonkong" dynamic, which underscores the robust capital-raising capabilities of Hong Kong stocks. Previously, renowned U.S. hedge fund manager David Tepper advocated for acquiring all China-related assets. However, earlier on, RaffAello Securities (HK) Ltd., known as the designated agent for tycoons, had quietly taken action to assist enterprises in expanding and strengthening their operations. The latest company to leverage RaffAello’s expertise to enhance its market presence is Shenzhen HQVT Technology Co., Ltd. (“HQVT”). As a leading firm specializing in AI algorithms and products in China, HQVT plays a crucial role in big data by comprehensively perceiving the physical world and making informed decisions. Collaborating with world-renowned experts in artificial intelligence, optical systems, operating systems, and file systems, HQVT continuously explores various domains within smart cities. The company has developed over 100 algorithms utilizing deep learning techniques across multiple spectra, including visible light, near-infrared, far-infrared, acoustic waves, millimeter waves, and terahertz, garnering widespread acclaim across various projects. HQVT's partners include Alibaba Cloud, China Railway Group (HKSE: 0390), CRRC Corporation (HKSE: 1766), and SenseTime (HKSE: 0020). Earlier this year, during one of the market's most challenging periods, RaffAello successfully raised USD 10 million for the Hong Kong fashion label Paprika, with investors including Franklin Templeton’s Asia Pacific Structured Equity Fund LPF, showcasing RaffAello's impressive fundraising capabilities. HQVT has previously completed multiple rounds of financing, with investors such as Shenzhen HTI Group and Shenzhen Fountain Investment Management Ltd. Additionally, Zheshang Venture Capital Co., Ltd. (NEEQ: 834089), listed on the New Third Board, has participated in two rounds of financing, further indicating that HQVT's potential has yet to be fully realized. In this latest venture, the RaffAello Opportunity Fund and Asia Pacific Structured Equity Fund will each invest HKD 75 million, becoming shareholders in HQVT and joining forces with prominent Chinese investment institutions. Over the years, RaffAello has successfully introduced significant family capital from notable figures such as Henderson’s Peter Lee and CK Life Sciences into a number of Hong Kong-listed companies, including China Wantian Holdings Ltd., Zhuguang Holdings Group Company Limited, and Purapharm Corporation Limited, thereby earning its reputation as the "Tycoon Designated Agent." As global competition in AI intensifies, HQVT is poised to emerge as a new star for China's artificial intelligence on the international stage.
Venture Capital
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
